A Multi-center, Phase Ia/Ib, Open Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
Latest Information Update: 06 Jul 2023
Price :
$35 *
At a glance
- Drugs Sytalizumab (Primary)
- Indications Carcinoma; Malignant melanoma; Urogenital cancer
- Focus Adverse reactions
- Sponsors Shandong TheraWisdom Biopharm
- 06 Jun 2023 Results (n=13; From Feb 2021 to Mar 2022) assessing the safety and efficacy of TWP-101 in patients with advanced melanoma and urothelial carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 10 May 2021 New trial record